NaNotics LLC is developing a nanomedical platform – called NaNots – for treating major diseases – including a broad range of cancers and inflammatory disorders – via depletion from blood of specific molecules that drive or enable those diseases. NaNots are injected like a drug and clear their targets quickly, deeply and safely: typically >95% target depletion in < 5 minutes, without measurable toxicity. NaNotics is in the late preclinical stage; we are about to announce a collaboration with a major oncology center for a first-in-human study of NaNots against a soluble tumor-generated immune inhibitor, for treating cancer. The NaNotics team invented the NaNot technology, which is now the subject of 12 granted patents, with many more pending. NaNotics is based in Mill Valley, CA, just north of San Francisco.
